Mazdutide

Status

Approved elsewhere. Approved in China: the NMPA approved mazdutide for chronic weight management in adults (Innovent announcement, 27 June 2025). No FDA approval found as of 28 September 2026, so there is no U.S. label.

What it is

A dual GLP-1 and glucagon receptor agonist, approved in China and studied mainly in Chinese trial populations.

What published research measured

A dual GLP-1 and glucagon receptor agonist based on the oxyntomodulin backbone, developed by Innovent and Eli Lilly and taken through phase 3 primarily in Chinese populations. Published trials report substantial weight reduction alongside glycaemic improvement, and the glucagon component is proposed to add an energy-expenditure effect that pure GLP-1 agonists lack. The trial base is real and recent, but it is geographically concentrated, and long-term cardiovascular outcome data of the kind that exists for the older incretins has not yet been reported. The glucagon arm of the mechanism has its own consequences to watch, including effects on heart rate and hepatic glucose output.

Source

Ji L et al. 2023, Nature Communications — phase 2 trial NCT04904913; Innovent NMPA approval announcement, 27 June 2025 Primary source

Sources

• Ji L et al. 2023, Nature Communications — phase 2 trial NCT04904913; Innovent NMPA approval announcement, 27 June 2025
• Manufacturer approval announcement
• 2025 high-dose phase-1 pharmacokinetics
• CDC handling principles
• ClinicalTrials.gov NCT04904913